Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Approximately 64% of endocrinologists prescribe GLP-1 receptor agonists as second-line therapy
The SURPASS-CVOT trial (estimated completion 2024) is evaluating long-term cardiovascular and other safety outcomes, including pancreatitis, in patients taking tirzepatide for up to 5 years
Lehr T, Staab A, Tillmann C, et al
FDA Access Data+1 In 2025, the FDA expanded Ozempics label to include reducing the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial
Injecting too shallowly, into the dermal layer, can cause pooling at the surface and injection site reactions including redness, swelling, and itching
Baseline: mean weight 111.4 kg (245.6 lb), mean BMI 40.4
US$ 28.26
US$ 26.00
US$ 24.11
US$ 23.86
US$ 25.24
